Our platform transiently and non-invasively disrupts the blood-brain barrier, allowing targeted delivery of CNS molecules previously unable to reach the brain
Our platform transiently and non-invasively disrupts the blood-brain barrier, allowing targeted delivery of CNS molecules previously unable to reach the brain. We collaborate with pharmaceutical and biotech partners to rescue assets sidelined by BBB constraints.